Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety diso...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

_Rocket Jul. 15 at 9:01 AM

$IXHL blatant manipulation aside, the price action on this stock is just absolute dogshit.

0 · Reply

Bullish449 Jul. 15 at 7:23 AM

$IXHL Out of 10mil market share 3.1mil in short? I assume BOD hold around 30pc of whole market share. So 3.1mil available share for short is bit scam? What do you guys think?

1 · Reply

J4y000 Jul. 15 at 7:06 AM

$IXHL surely they are dosing by now give us something Joel

0 · Reply

seams Jul. 15 at 4:11 AM

$IXHL For us, the focus is on continuing to de-risk our assets, progressing them at a rapid pace through the clinic and being able to provide key catalysts and milestones to the market,” Latham explained. First patient soon.....

0 · Reply

seams Jul. 15 at 4:09 AM

$IXHL

0 · Reply

seams Jul. 15 at 1:53 AM

$IXHL why so bearish, the overnight is pumping this is about to take off given the last few hours 🙃🙃🙃

0 · Reply

starkyboy Jul. 15 at 1:52 AM

$IXHL okay but what if this is all just part of an elaborate scheme? what if shareholder value is happening soon? what if we are simply counting down until launch? that'd be pretty neato, yeah?

2 · Reply

JackB2025 Jul. 15 at 1:51 AM

$IXHL I see it as a chance to top up / lower your SP average. Up to each person how they manage risk but I think stop losses are not worth it at this stage. This thing is a monster in the making and can fly at any moment now so I do not want to miss that bus when she leaves. Each to their own of course. GLTAHs

0 · Reply

D_Ko Jul. 15 at 1:02 AM

$IXHL

0 · Reply

Rampart1 Jul. 15 at 12:59 AM

$IXHL its testing support. since algos are controlling this just assume it will move with the market and algos usually test highs and lows entirely to trap bulls and then trigger stop losses. its evil.

0 · Reply

Incannex granted IHL-42X composition patent by USPTO

Jun 25, 2026, 8:00 AM EDT - 19 days ago

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

2026-06-10T12:06:25.000Z - 4 weeks ago

Incannex receives A$6.04M tax incentive refund

Jun 10, 2026, 8:00 AM EDT - 4 weeks ago

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Jun 9, 2026, 8:00 AM EDT - 5 weeks ago

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

2026-06-08T11:05:32.000Z - 5 weeks ago

Incannex initiated with a Buy at Alliance Global

May 15, 2026, 7:00 AM EDT - 2 months ago

Incannex Healthcare Quarterly report: Q3 2026

2026-05-14T19:10:49.000Z - 2 months ago

Incannex commences DReaMzz clinical study of IHL-42X in OSA

May 14, 2026, 10:35 AM EDT - 2 months ago

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

May 12, 2026, 8:00 AM EDT - 2 months ago

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

May 7, 2026, 10:00 AM EDT - 2 months ago

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

2026-03-27T12:12:54.000Z - 3 months ago

Incannex reactivates share repurchase program

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

2026-03-25T12:11:47.000Z - 3 months ago

Incannex enters partnership agreement with American Academy of Sleep Medicine

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

2026-03-18T12:27:15.000Z - 4 months ago

Incannex reports balance sheet with $75M in cash, no debt

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

2026-03-17T12:16:04.000Z - 4 months ago

Incannex regains compliance with Nasdaq minimum bid price rule

Mar 17, 2026, 8:00 AM EDT - 4 months ago

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-03-12T12:27:43.000Z - 4 months ago

Incannex prices 2M shares at $5.00 in registered direct offering

2026-03-12T12:21:15.000Z - 4 months ago

Incannex announces enhanced development strategy for IHL-42X

Mar 12, 2026, 8:05 AM EDT - 4 months ago

Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2026-02-27T00:50:18.000Z - 4 months ago

Incannex Healthcare Inc trading halted, news pending

2026-02-25T14:29:04.000Z - 4 months ago

Incannex board approves 1-for-30 reverse stock split

Feb 25, 2026, 9:20 AM EST - 4 months ago

Incannex Announces Reverse Stock Split

Feb 20, 2026, 6:00 AM EST - 5 months ago

Incannex Healthcare Slides: Investor presentation

Feb 18, 2026, 6:35 PM EST - 5 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Feb 13, 2026, 7:00 AM EST - 5 months ago

Incannex Healthcare Quarterly report: Q2 2026

2026-01-29T13:16:52.000Z - 5 months ago

Incannex announces additional appointments to Clinical Advisory Board

Jan 29, 2026, 8:00 AM EST - 5 months ago

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

2026-01-22T13:21:38.000Z - 6 months ago

Incannex announces formation of clinical advisory board for PSX-001 program

Jan 22, 2026, 8:00 AM EST - 6 months ago

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Jan 15, 2026, 8:00 AM EST - 6 months ago

Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards

Jan 14, 2026, 8:00 AM EST - 6 months ago

Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

Dec 18, 2025, 7:00 AM EST - 7 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Dec 16, 2025, 7:00 AM EST - 7 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Dec 3, 2025, 8:00 AM EST - 7 months ago

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

Nov 20, 2025, 9:34 AM EST - 8 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026

Nov 14, 2025, 4:00 PM EST - 8 months ago

Incannex Healthcare Quarterly report: Q1 2026

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

Oct 27, 2025, 8:00 AM EDT - 9 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 9 months ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Sep 29, 2025, 9:30 AM EDT - 10 months ago

Incannex Healthcare Annual report: Q4 2025

Aug 26, 2025, 8:00 AM EDT - 11 months ago

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Aug 22, 2025, 8:00 AM EDT - 11 months ago

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Aug 19, 2025, 4:29 PM EDT - 11 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Jul 25, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Jun 24, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 1 year ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 1 year ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 16, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

May 15, 2025, 9:30 AM EDT - 1 year ago

Incannex Healthcare Earnings release: Q3 2025

May 15, 2025, 9:30 AM EDT - 1 year ago

Incannex Healthcare Quarterly report: Q3 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Mar 7, 2025, 2:10 PM EST - 1 year ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 14, 2025, 7:00 AM EST - 1 year ago

Incannex Healthcare Earnings release: Q2 2025

Feb 14, 2025, 7:00 AM EST - 1 year ago

Incannex Healthcare Quarterly report: Q2 2025

Feb 4, 2025, 9:15 AM EST - 1 year ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 26, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Nov 14, 2024, 4:05 PM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Nov 14, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Earnings release: Q1 2025

Nov 14, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Quarterly report: Q1 2025

Nov 12, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Incannex Healthcare Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Incannex Healthcare Proxy statement: Proxy Filing

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

_Rocket Jul. 15 at 9:01 AM

$IXHL blatant manipulation aside, the price action on this stock is just absolute dogshit.

0 · Reply

Bullish449 Jul. 15 at 7:23 AM

$IXHL Out of 10mil market share 3.1mil in short? I assume BOD hold around 30pc of whole market share. So 3.1mil available share for short is bit scam? What do you guys think?

1 · Reply

J4y000 Jul. 15 at 7:06 AM

$IXHL surely they are dosing by now give us something Joel

0 · Reply

seams Jul. 15 at 4:11 AM

0 · Reply

seams Jul. 15 at 4:09 AM

$IXHL

0 · Reply

seams Jul. 15 at 1:53 AM

$IXHL why so bearish, the overnight is pumping this is about to take off given the last few hours 🙃🙃🙃

0 · Reply

starkyboy Jul. 15 at 1:52 AM

$IXHL okay but what if this is all just part of an elaborate scheme? what if shareholder value is happening soon? what if we are simply counting down until launch? that'd be pretty neato, yeah?

2 · Reply

JackB2025 Jul. 15 at 1:51 AM

0 · Reply

D_Ko Jul. 15 at 1:02 AM

$IXHL

0 · Reply

Rampart1 Jul. 15 at 12:59 AM

0 · Reply

Santa_Claus_Trades Jul. 15 at 12:01 AM

$IXHL Closed at .40. Pardon my French, but that's godddddamn ridiculous.

3 · Reply

D_Ko Jul. 14 at 11:56 PM

$IXHL Joel your in the grave yard

0 · Reply

D_Ko Jul. 14 at 11:43 PM

$IXHL Joel is looking for the 1600% gain but it ain't coming guys ...I can list success biotech CEOs but Joel ain't one

0 · Reply

Chapman211 Jul. 14 at 10:42 PM

$IXHL depressing is an understatement.

2 · Reply

Rasputi Jul. 14 at 10:34 PM

$IXHL 20k buy, welcome bro

1 · Reply

LN1990 Jul. 14 at 10:30 PM

$IXHL comically poor, not a serious player.

0 · Reply

seams Jul. 14 at 10:25 PM

$IXHL For Incannex, the next stage of development will depend on whether its dose-optimization work can produce a stronger, more targeted Phase III strategy. !!! Latham said the dose-optimization study is designed to help determine whether different dosing approaches may be better suited to different subsets of patients. That could be important in a heterogeneous condition like OSA, where severity, underlying physiology, comorbidities and patient experience can vary widely.???? Good luck with that JDawg

1 · Reply

Santa_Claus_Trades Jul. 14 at 10:20 PM

$IXHL Well at least we're trying to claw our way back from .17. Level two looks pretty good after .26....

0 · Reply

Santa_Claus_Trades Jul. 14 at 10:00 PM

$IXHL Anyone notice the picture below is showing Joel's picture, but listing him as Daniel M. Schmitt? Daniel M. Schmitt is the President, Chief Executive Officer, and Director of Actuate Therapeutics, Inc.

3 · Reply

Santa_Claus_Trades Jul. 14 at 9:42 PM

$IXHL FWIW... https://xtalks.com/incannex-healthcares-site-strategy-for-obstructive-sleep-apnea-drug-development-4856/

0 · Reply

macdub8 Jul. 14 at 9:41 PM

$IXHL The IXHL special

0 · Reply

macdub8 Jul. 14 at 9:41 PM

$IXHL Joel starting his first senior exec role at 3 years old

0 · Reply

Market Cap	39.60M
Revenue (ttm)	90,000.00
Net Income (ttm)	-46.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52,100.00%
Debt to Equity Ratio	0.00

Volume	300,400
Avg Vol	288,332
Day's Range	N/A - N/A
Shares Out	11.97M
Stochastic %K	2%
Beta	6.95
Analysts	Hold
Price Target	$18.00